BRIEF-Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM

Reuters

27 Mar

BRIEF-Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM

March 27 (Reuters) - BridgeBio Pharma Inc BBIO.O:

BEYONTTRA™ (ACORAMIDIS), THE FIRST NEAR-COMPLETE TTR STABILIZER (≥90%), APPROVED IN JAPAN TO TREAT ATTR-CM
BRIDGEBIO PHARMA- WILL RECEIVE A $30 MILLION MILESTONE PAYMENT UPON APPROVAL IN JAPAN
BRIDGEBIO PHARMA INC - WILL GET ROYALTIES IN LOW DOUBLE DIGITS ON SALES OF ACORAMIDIS IN JAPAN

Source text: ID:nGNE6VhzHP

Further company coverage: BBIO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2522374883"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522374883\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522374883?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-27 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522374883","market":"nz","top_or_hot":-1,"title":"BRIEF-Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM</title></head><body><p><span>March 27 (Reuters)</span><span> - </span>BridgeBio Pharma Inc <span>BBIO.O</span>:</p><ul><li><p>BEYONTTRA™ (ACORAMIDIS), THE FIRST NEAR-COMPLETE TTR STABILIZER (≥90%), APPROVED IN JAPAN TO TREAT ATTR-CM</p></li><li><p>BRIDGEBIO PHARMA- WILL RECEIVE A $30 MILLION MILESTONE PAYMENT UPON APPROVAL IN JAPAN</p></li><li><p>BRIDGEBIO PHARMA INC - WILL GET ROYALTIES IN LOW DOUBLE DIGITS ON SALES OF ACORAMIDIS IN JAPAN</p></li></ul><p>Source text: <span>ID:nGNE6VhzHP</span></p><p>Further company coverage: <span>BBIO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-27 19:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CM</title></head><body><p><span>March 27 (Reuters)</span><span> - </span>BridgeBio Pharma Inc <span>BBIO.O</span>:</p><ul><li><p>BEYONTTRA™ (ACORAMIDIS), THE FIRST NEAR-COMPLETE TTR STABILIZER (≥90%), APPROVED IN JAPAN TO TREAT ATTR-CM</p></li><li><p>BRIDGEBIO PHARMA- WILL RECEIVE A $30 MILLION MILESTONE PAYMENT UPON APPROVAL IN JAPAN</p></li><li><p>BRIDGEBIO PHARMA INC - WILL GET ROYALTIES IN LOW DOUBLE DIGITS ON SALES OF ACORAMIDIS IN JAPAN</p></li></ul><p>Source text: <span>ID:nGNE6VhzHP</span></p><p>Further company coverage: <span>BBIO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBIO","symbol_name":"BridgeBio Pharma, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nFWN3QA089:1","article_id":"2522374883","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522374883","pubTimestamp":1743075680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Beyonttra (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CMMarch 27 (Reuters) - BridgeBio Pharma Inc BBIO.O:BEYONTTRA (ACORAMIDIS), THE FIRST NEAR-C","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BBIO":"BridgeBio Pharma, Inc.","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4505":"高瓴资本持仓","BK4588":"碎股"},"translate_title":"BRIEF-Beyonttra™（Acoramidis），首个接近完全TTR稳定剂（≥90%），在日获批治疗ATTR-CM","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":0.9},"content_text":"BRIEF-Beyonttra™ (Acoramidis), The First Near-Complete TTR Stabilizer (≥90%), Approved in Japan To Treat ATTR-CMMarch 27 (Reuters) - BridgeBio Pharma Inc BBIO.O:BEYONTTRA™ (ACORAMIDIS), THE FIRST NEAR-COMPLETE TTR STABILIZER (≥90%), APPROVED IN JAPAN TO TREAT ATTR-CMBRIDGEBIO PHARMA- WILL RECEIVE A $30 MILLION MILESTONE PAYMENT UPON APPROVAL IN JAPANBRIDGEBIO PHARMA INC - WILL GET ROYALTIES IN LOW DOUBLE DIGITS ON SALES OF ACORAMIDIS IN JAPANSource text: ID:nGNE6VhzHPFurther company coverage: BBIO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}